



PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce, Govt. of India)

COPY

Date : 11-05-2010

News / Story reproduced with thanks:- Money control

Merck, Glenmark ink out-of-court settlement for Zetia

Direct link to the News/Story:-

http://www.moneycontrol.com/news/business/merck-glenmark-ink-out-of-court-settlement-for-zetia_456963.html

Merck and [Glenmark](#) have gone in for a out-of-court settlement for the drug Zetia, reports CNBC-TV18. Glenmark can now launch Zetia four months ahead of its patent expiry. The settlement ends the lawsuit that was scheduled to begin tomorrow.

On May 4, CNBC-TV18 reported that Par Pharmaceutical has entered into an exclusive licencing agreement with Glenmark Generics for Zetia. Under the terms of the licencing and supply agreement, the US-based specialty pharmaceutical company has made a payment to Glenmark for exclusive rights to market, sell and distribute ezetimibe 10 mg tablets, the generic version of Merck & Co's Zetia in the US. Zetia is a cholesterol modifying agent with annual US sales of about USD 1.4 billion.

Glenmark is currently involved in patent litigation concerning ezetimibe in the US District Court for the District of New Jersey, a company release said.